Raphael Pharmaceutical (RAPH) Free Cash Flow Growth (1y) (2021 - 2025)
Raphael Pharmaceutical (RAPH) Free Cash Flow Growth (1y) (2021 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 10.34% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -13.65% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 56.40% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -5.85% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -29.32% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 166.91% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 44.93% |
| 10 | Raphael Pharmaceutical | 27.37 Mn | 27.33 Mn | - | 174.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 174.19% |
| Sep 30, 2025 | 78.75% |
| Jun 30, 2025 | 86.24% |
| Mar 31, 2025 | -20.81% |
| Dec 31, 2024 | 29.55% |
| Sep 30, 2024 | 84.03% |
| Jun 30, 2024 | -1.40% |
| Mar 31, 2024 | 56.64% |
| Dec 31, 2023 | 68.23% |
| Sep 30, 2023 | -229.61% |
| Jun 30, 2023 | 13.31% |
| Mar 31, 2023 | -386.59% |
| Dec 31, 2022 | 60.65% |
| Sep 30, 2022 | 45.91% |
| Jun 30, 2022 | 18.69% |
| Mar 31, 2022 | 36.43% |
| Dec 31, 2021 | -50.43% |